Name of partner: Evotec , Toulouse, France.
Name of leader: Nathalie Alet
Objectives: to identify metabolic genes that are modulated or mutated in acute myeloid leukemia patient samples. Set up in vivo model(s) suitable for validation of their interest.
Expected Results: We will model a metabolic gene profile in acute myeloid leukemia and link this gene profile to patient outcome according to the treatment received. Then drugs/compounds potentially modulating the metabolic profile in a beneficial way may be tested in vivo.
The new work developed in the lab of META-CAN’s coordinator, Cristina Muñoz-Pinedo, has finally seen the light in a paper at PNAS. The study has been possible thanks to an amazing group of researchers and the funding of two MSCA Actions: TRAINERS (GA 675448) and META-CAN (GA 766214).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
